GlassScriptPhysician profile
Joon Y Kim
NPI 1942295233
$2,430.77
in general payments reported to CMS, 2019-2025
28 companies · $270 in 2025
The $270 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $803 · 2020: $176 · 2021: $85.04 · 2022: $234 · 2023: $431 · 2024: $431 · 2025: $270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,132.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $546.78 | 2019-2025 | Clareon, Unity, Simbrinza |
| Horizon Therapeutics Plc | $300.51 | 2020-2023 | Tepezza |
| Eyepoint US, INC. | $250.00 | 2019 | |
| Alcon Research LLC | $141.40 | 2024 | Acrysof Iq Vivity |
| Bausch & Lomb Americas INC. | $127.57 | 2022-2025 | Xiidra, Vyzulta, Miebo |
| Alimera Sciences, INC. | $127.49 | 2019 | |
| Novartis Pharmaceuticals Corporation | $113.86 | 2019-2022 | |
| Pfizer INC. | $111.97 | 2019 | |
| Harrow Eye, LLC | $82.87 | 2024-2025 | Vevye |
| Abbvie INC. | $73.53 | 2022-2025 | |
| Carl Zeiss Meditec, INC. | $69.56 | 2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $68.48 | 2019-2021 | |
| New World Medical,INC. | $45.04 | 2022 | |
| Rxsight INC | $43.16 | 2023 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Kala Pharmaceuticals, INC. | $42.12 | 2020-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $41.27 | 2022-2023 | Cequa |
| Sight Sciences, INC. | $38.92 | 2021-2022 | |
| Dompe US, INC. | $24.47 | 2022 | |
| Ocular Therapeutix, INC. | $23.64 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $23.57 | 2024 | Xdemvy |
| Shire North American Group INC | $21.37 | 2019 | |
| Amgen INC. | $20.60 | 2024 | Tepezza |
| Thea Pharma INC. | $20.11 | 2023 | Iyuzeh |
| Eyevance Pharmaceuticals LLC | $18.91 | 2019 | |
| Oyster Point Pharma, INC. | $18.81 | 2023 | Tyrvaya |
| Astellas Pharma US INC | $18.33 | 2024 | Izervay |
| Johnson & Johnson Surgical Vision, INC. | $16.43 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joon Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.